Navigation Links
Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohn's Disease and Ulcerative Colitis in the United States
Date:6/21/2013

estimates and assumptions made by management that are believed to be reasonable, though they are inherently uncertain and difficult to predict. Investors are cautioned not to unduly rely on such forward-looking statements.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Some of these risks and uncertainties include, but are not limited to, (1) the economic circumstances surrounding Takeda's business, including general economic conditions in Japan, the United States and worldwide; (2) competitive pressures and developments; (3) applicable laws and regulations; (4) the success or failure of product development programs; (5) actions of regulatory authorities and the timing thereof; (6) changes in exchange rates; (7) claims or concerns regarding the safety or efficacy of marketed products or product candidates in development; and (8) integration activities with acquired companies.

The forward-looking statements contained in this press release speak only as of the date of this press release, and Takeda undertakes no obligation to revise or update any forward-looking statements to reflect new information, future events or circumstances after the date of the forward-looking statement. If Takeda does update or correct one or more of these statements, investors and others should not conclude that Takeda will make additional updates or corrections.


'/>"/>
SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
2. AGA Research Foundation Announces Endowment Gift from Takeda Pharmaceuticals U.S.A., Inc. to Support Gastroenterology Research
3. Takeda to Acquire Inviragen, Inc.
4. Takeda Responds to Verdict in Diabetes Drug Case
5. Takeda Launches New Subsidiary in Ecuador
6. Takeda lanza nueva subsidiaria en Ecuador
7. Scripps Research Institute and Takeda Pharmaceuticals Announce Expanded Research Collaboration
8. Takeda presenta la richiesta di autorizzazione allimmissione in commercio nellUnione Europea per Vedolizumab nella colite ulcerosa moderata-grave e nella malattia di Crohn
9. Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohns Disease in the European Union
10. Takeda and Resolve Therapeutics Enter Autoimmune Partnership
11. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  MedScope ( www.medscope.org ), ... nominated for a 2015 Connected World magazine ... Response System (mPERS), that can be used anywhere, anytime. ... partner.  In nominating MedScope, Landon ...
(Date:1/23/2015)... all-time hits leader, is the new spokesperson for the topical ... announced. "Pete,s a Hall of Famer in our ... with Myoflex," said Ducere Pharma Chief Executive Officer Chris ... across all generations. The passion and intensity that Pete brought ...
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: ... Phase I trial of Lixte,s lead compound, LB‑100, is being ... John S. Kovach , M.D., the founder and ... to be completed at a single site. Accrual of patients, ...
Breaking Medicine Technology:MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2Pete Rose bets on Myoflex to relieve aches and pains 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... , SOUTH PLAINFIELD, N.J. , ... announced the initiation of an additional clinical trial of ataluren ... Becker muscular dystrophy (nmDBMD) who have permanently lost the ... methods for measuring functional abilities in patients who have lost ...
... , NEW YORK , Jan. 19 ... Increase Exposure to Non-Cyclical, Laggard Sectors; Maintain Exposure to US ... phase of recovery is over, markets are moving into a ... investors are paying more attention to valuations, particularly in the ...
Cached Medicine Technology:PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy 2PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy 3PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy 4PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy 5PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy 6Barclays Wealth Recommends Increasing Exposure to Laggard Sectors Including Consumer Staples, Pharmaceuticals and Telecoms 2Barclays Wealth Recommends Increasing Exposure to Laggard Sectors Including Consumer Staples, Pharmaceuticals and Telecoms 3Barclays Wealth Recommends Increasing Exposure to Laggard Sectors Including Consumer Staples, Pharmaceuticals and Telecoms 4
(Date:1/22/2015)... 2015 The City of West Hollywood hosted a ... commemorate the 42nd anniversary of the Supreme Court decision Roe v. ... 42 years since the Roe vs. Wade decision and the fight ... as ever,” said City of West Hollywood Councilmember Abbe Land. “We ...
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the release of ... kids with cancer. The Chemo Duck App, available on iTunes for ... games to help children of all ages living with cancer adjust ... kids entertained, educated and at ease while waiting for clinic visits ...
(Date:1/22/2015)... January 23, 2015 VogueQueen is a seasoned ... prices and many designers are thrilled to have it lead ... announces its new collection of prom dresses for the global ... drive the strategic vision and he focuses on continuing the ...
(Date:1/22/2015)... is a famous wedding dress company offering many trendy designs. ... Facebook, Twitter, and Pinterest. The fans will have an opportunity ... every week. , Moreover, the company has extended its 2015 ... homepage for more information. , Angelweddingdress is a ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently released ... website of AngelWeddingDress.com to find more details. , ... for a bridal party. AngelWeddingDress offers a variety of ... maternity wedding dresses are specially designed for 2015. , ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2
... by the state-owned Hindustan Latex Ltd., will be launched next ... we had test marketed 30,000 pieces of female condoms across ... and women, we have decided it is time to enter ... major cities of the country,' M. Ayyappan, chairman and managing ...
... Andhra women have financed the bypass surgery of a fisherwoman ... to their efforts, B. Hemavati, 35, wife of a fisherman ... operation at the Tirupati-based Sri Venkateswara Institute of Medical Sciences ... Godavari district, was diagnosed with a heart ailment that doctors ...
... study it has been found that a herbal supplement can ... (NAC) which is a potential agent to modulate the effects ... models for the treatment of heroin addiction, and possibly alcoholism. ... herbal supplement known for its antioxidant effects. Antioxidants are agents ...
... beam computerized tomography (CBCT) is increasingly becoming a potent ... ,J. Martin Palomo and Mark Hans from the ... School of Dental Medicine and C.H. Kau and S. ... sciences at the University of Wales' College of Medicine ...
... his team from Gladstone Institute of Neurological Disease have ... for causing Alzheimer's disease //that acts by inactivating the ... to the protein fragments released from apoE. ... causing Alzheimer’s disease by not providing the glucose present ...
... important gene has been identified by the Oregon National ... (OHSU) researchers, which appears to control stem cells becoming ... conditions like Parkinson's disease and brain injury as a ... into neurons, in the early stages before birth, which ...
Cached Medicine News:Health News:Poor Andhra Women Enable Bypass Surgery Paying 50 Paise Each 2Health News:A herbal drug addiction releiver 2Health News:New Computerized Imaging Systems Help In Better Dental Treatment Planning 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: